title: The effects of platelet-activating factor on the secretion of interleukin-8 and growth-regulated oncogene alpha in human immortalized granulosa cell line (GC1a).
abstract: OBJECTIVE
  To investigate the role of platelet-activating factor (PAF) in human ovulation, we studied the regulation of interleukin (IL)-8 and growth-regulated oncogene (GRO) alpha in cultured human immortalized granulosa cell line (GC1a).
  
  
  METHODS
  GC1a was cultured in serum-free medium, and incubated with carbamyl-PAF (C-PAF) and/or PAF receptor antagonist (WEB 2086). The supernatants were collected, and IL-8 and GRO alpha were measured by enzyme-linked immunosorbent assay.
  
  
  RESULTS
  After treatment with C-PAF, the levels of IL-8 and GROalpha increased in a time-dependent manner. The levels of IL-8 and GROalpha were significantly increased after treatment with C-PAF in a dose-dependent manner. However, the levels of IL-8 and GROalpha were significantly decreased by treatment with C-PAF and with increasing concentrations of WEB 2086.
  
  
  CONCLUSIONS
  Our data indicated that IL-8 and GROalpha were regulated by C-PAF. The results suggested that PAF may play an important role in human pre-ovulatory processes involving IL-8 and GROalpha production.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Oita, Japan. kawayas@med.oita-u.ac.jp
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Kawano
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Furukawa
authors.forename: Junichiro
authors.initials: J
authors.lastname: Fukuda
authors.forename: Harunobu
authors.initials: H
authors.lastname: Matsumoto
authors.forename: Akitoshi
authors.initials: A
authors.lastname: Yuge
authors.forename: Hisashi
authors.initials: H
authors.lastname: Narahara
mesh_terms: D001381:Azepines / Q000494:pharmacology; D002460:Cell Line; D054360:Chemokine CXCL1 / Q000096:biosynthesis / Q000276:immunology / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006107:Granulosa Cells / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D016209:Interleukin-8 / Q000096:biosynthesis / Q000276:immunology / Q000378:metabolism*; D010060:Ovulation; D010742:Phospholipid Ethers / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000276:immunology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors / Q000276:immunology; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors / Q000276:immunology; D014230:Triazoles / Q000494:pharmacology
chemical_list: D001381:Azepines; C475829:CXCL1 protein, human; D054360:Chemokine CXCL1; D016209:Interleukin-8; D010742:Phospholipid Ethers; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; D043562:Receptors, G-Protein-Coupled; D014230:Triazoles; C039351:platelet activating factor receptor; C052518:WEB 2086; C053479:1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine